196 related articles for article (PubMed ID: 37078220)
21. Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection.
Choi SH; Park JY; Kweon OJ; Park JH; Kim MC; Lim Y; Chung JW
J Korean Med Sci; 2023 May; 38(20):e155. PubMed ID: 37218354
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2.
Nickel O; Rockstroh A; Wolf J; Landgraf S; Kalbitz S; Kellner N; Borte M; Pietsch C; Fertey J; Lübbert C; Ulbert S; Borte S
PLoS One; 2022; 17(10):e0263861. PubMed ID: 36256664
[TBL] [Abstract][Full Text] [Related]
23. Assessment of antibody dynamics and neutralizing activity using serological assay after SARS-CoV-2 infection and vaccination.
Takahashi T; Ai T; Saito K; Nojiri S; Takahashi M; Igawa G; Yamamoto T; Khasawneh A; Paran FJ; Takei S; Horiuchi Y; Kanno T; Tobiume M; Hiki M; Wakita M; Miida T; Okuzawa A; Suzuki T; Takahashi K; Naito T; Tabe Y
PLoS One; 2023; 18(9):e0291670. PubMed ID: 37725623
[TBL] [Abstract][Full Text] [Related]
24. Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination.
Assawakosri S; Kanokudom S; Chansaenroj J; Suntronwong N; Auphimai C; Nilyanimit P; Vichaiwattana P; Thongmee T; Duangchinda T; Chantima W; Pakchotanon P; Srimuan D; Thatsanatorn T; Klinfueng S; Sudhinaraset N; Mongkolsapaya J; Wanlapakorn N; Honsawek S; Poovorawan Y
Int J Infect Dis; 2022 Sep; 122():793-801. PubMed ID: 35863731
[TBL] [Abstract][Full Text] [Related]
25. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
26. Trends of humoral immune responses to heterologous antigenic exposure due to vaccination & omicron SARS-CoV-2 infection: Implications for boosting.
Batra G; Murugesan DR; Raghavan S; Chattopadhyay S; Mehdi F; Ayushi ; Gosain M; Singh S; Das SJ; Deshpande S; Sonar S; Jakhar K; Bhattacharya J; Mani S; Pandey AK; Sankalp ; Goswami S; Das A; Dwivedi T; Sharma N; Kumar S; Sharma P; Kapoor S; Kshetrapa P; Wadhwa N; Thiruvengadam R; Kumar R; Gupta R; Garg PK; Bhatnagar S
Indian J Med Res; 2023 Jun; 157(6):509-518. PubMed ID: 37322634
[TBL] [Abstract][Full Text] [Related]
27. Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants.
Seki Y; Yoshihara Y; Nojima K; Momose H; Fukushi S; Moriyama S; Wagatsuma A; Numata N; Sasaki K; Kuzuoka T; Yato Y; Takahashi Y; Maeda K; Suzuki T; Mizukami T; Hamaguchi I
Med; 2022 Jun; 3(6):406-421.e4. PubMed ID: 35815933
[TBL] [Abstract][Full Text] [Related]
28. Trajectory of Humoral Responses to Two Doses of ChAdOx1 nCoV-19 Vaccination in Patients Receiving Maintenance Hemodialysis.
Ling TC; Chen PL; Li NY; Ko WC; Sun CY; Chao JY; Shieh CC; Shen CF; Wu JL; Huang TC; Chao CH; Wang JR; Chang YT
Microbiol Spectr; 2023 Feb; 11(2):e0344522. PubMed ID: 36809164
[TBL] [Abstract][Full Text] [Related]
29. Serum neutralization of SARS coronavirus 2 Omicron sublineages BA.1 and BA.2 and cellular immune responses 3 months after booster vaccination.
Alidjinou EK; Demaret J; Corroyer-Simovic B; Vuotto F; Miczek S; Labreuche J; Goffard A; Trauet J; Lupau D; Dendooven A; Huvent-Grelle D; Podvin J; Dreuil D; Faure K; Deplanque D; Bocket L; Duhamel A; Sobaszek A; Hober D; Hisbergues M; Puisieux F; Autran B; Yazdanpanah Y; Labalette M; Lefèvre G
Clin Microbiol Infect; 2023 Feb; 29(2):258.e1-258.e4. PubMed ID: 36257549
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity of a Fractional Dose of mRNA BNT162b2 COVID-19 Vaccine for Primary Series and Booster Vaccination among Healthy Adolescents.
Puthanakit T; Chantasrisawad N; Yoohat K; Nantanee R; Sophonphan J; Meepuksom T; Sodsai P; Phanthanawiboon S; Jantarabenjakul W; Hirankarn N; Kosalaraksa P
Vaccines (Basel); 2022 Sep; 10(10):. PubMed ID: 36298510
[TBL] [Abstract][Full Text] [Related]
31. Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2.
Malipiero G; D'Agaro P; Segat L; Moratto A; Villalta D
Clin Chim Acta; 2022 Jan; 524():11-17. PubMed ID: 34843705
[TBL] [Abstract][Full Text] [Related]
32. Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection.
Gilboa M; Regev-Yochay G; Mandelboim M; Indenbaum V; Asraf K; Fluss R; Amit S; Mendelson E; Doolman R; Afek A; Freedman LS; Kreiss Y; Lustig Y
JAMA Netw Open; 2022 Sep; 5(9):e2231778. PubMed ID: 36107426
[TBL] [Abstract][Full Text] [Related]
33. Validation of a SARS-CoV-2 Surrogate Neutralization Test Detecting Neutralizing Antibodies against the Major Variants of Concern.
Santos da Silva E; Servais JY; Kohnen M; Arendt V; Staub T; The Con-Vince Consortium ; The CoVaLux Consortium ; Krüger R; Fagherazzi G; Wilmes P; Hübschen JM; Ollert M; Perez-Bercoff D; Seguin-Devaux C
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834413
[TBL] [Abstract][Full Text] [Related]
34. Estimation of SARS-CoV-2 Neutralizing Activity and Protective Immunity in Different Vaccine Types Using Three Surrogate Virus Neutralization Test Assays and Two Semiquantitative Binding Assays Targeting the Receptor-Binding Domain.
Lee B; Ko JH; Lee KH; Kim YC; Song YG; Park YS; Baek YJ; Ahn JY; Choi JY; Song KH; Kim ES; Bae S; Kim SH; Jeong HW; Kim SW; Kwon KT; Kim SH; Jeong H; Kim B; Kim SS; Choi WS; Peck KR; Kang ES
Microbiol Spectr; 2022 Dec; 10(6):e0266922. PubMed ID: 36250875
[TBL] [Abstract][Full Text] [Related]
35. A SARS-CoV-2 Label-Free Surrogate Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics in COVID-19 Patients.
Luo YR; Yun C; Chakraborty I; Wu AHB; Lynch KL
J Clin Microbiol; 2021 Jun; 59(7):e0019321. PubMed ID: 33827900
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity of BNT162b2 Vaccination against SARS-CoV-2 Omicron Variant and Attitudes toward a COVID-19 Booster Dose among Healthy Thai Adolescents.
Assavavongwaikit P; Chantasrisawad N; Himananto O; Phasomsap C; Klawaja P; Cartledge S; Nadsasarn R; Jupimai T; Kawichai S; Anugulruengkitt S; Puthanakit T; On Behalf Of The Study Team
Vaccines (Basel); 2022 Jul; 10(7):. PubMed ID: 35891264
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic performance between in-house and commercial SARS-CoV-2 serological immunoassays including binding-specific antibody and surrogate virus neutralization test (sVNT).
Winichakoon P; Wipasa J; Chawansuntati K; Salee P; Sudjaritruk T; Yasri S; Khamwan C; Peerakam R; Dankai D; Chaiwarith R
Sci Rep; 2023 Jan; 13(1):34. PubMed ID: 36593231
[TBL] [Abstract][Full Text] [Related]
38. Performance evaluation of the Ortho VITROS SARS-CoV-2 Spike-Specific Quantitative IgG test by comparison with the surrogate virus neutralizing antibody test and clinical assessment.
Takahashi M; Saito K; Ai T; Nojiri S; Khasawneh A; Paran FJ; Horiuchi Y; Takei S; Yamamoto T; Wakita M; Hiki M; Miida T; Naito T; Takahashi K; Tabe Y
PLoS One; 2023; 18(1):e0279779. PubMed ID: 36693058
[TBL] [Abstract][Full Text] [Related]
39. SARS-CoV-2 Infection-and mRNA Vaccine-induced Humoral Immunity among Schoolchildren in Hawassa, Ethiopia.
Merid Y; Tekleselasie W; Tesfaye E; Gadisa A; Fentahun D; Abate A; Alemu A; Mihret A; Mulu A; Gelanew T
Front Immunol; 2023; 14():1163688. PubMed ID: 37398668
[TBL] [Abstract][Full Text] [Related]
40. Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2.
Favresse J; Gillot C; Di Chiaro L; Eucher C; Elsen M; Van Eeckhoudt S; David C; Morimont L; Dogné JM; Douxfils J
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]